Cardiac Risks Associated with Domperidone and Metoclopramide

Introduction to Cardiac Risks

• The National Patient Safety Agency recommends QTc monitoring for patients taking Domperidone due to its risk of QTc prolongation, with a low safety margin, especially at doses over 30 mg/day 1, 2, 3.
• The European Medicines Agency advises against long-term use of Metoclopramid due to extrapyramidal side effects and potential irreversible tardive dyskinesia in older patients, in addition to its cardiac risks 1, 2, 3.

Patient-Specific Risk Factors

• Female gender and age >65 years increase susceptibility to QTc prolongation 6.
• Baseline QTc >500 ms is a contraindication for both medications 6.
• Electrolyte disturbances, particularly hypokalemia and hypomagnesemia, enhance the risk of QTc prolongation and arrhythmias 7, 6.
• Concurrent use of other QTc-prolonging medications (e.g., Moxifloxacin, Ondansetron, antipsychotics) produces additive effects 4, 5, 6.
• Pre-existing cardiovascular diseases require special caution when using either medication 6.

Monitoring and Management

• Baseline EKG is obligatory before starting therapy with either medication 5, 6.
• Electrolyte correction (potassium >4 mM/L, magnesium normalization) is necessary before therapy initiation 7, 5.
• Follow-up EKG is recommended after dose titration 6.
• Medication should be discontinued if QTc >500 ms or increases by >60 ms from baseline 5, 6.

Alternative Therapies

• Prucaloprid, a 5-HT4 receptor agonist, does not affect the QT interval and may be considered as an alternative with lower cardiac risk 1, 2, 3.
• Erythromycin, a motilin agonist, can be useful in certain conditions but is subject to tachyphylaxis 1, 2, 3.